Steven has worked as a financial professional for over 30 years with both extensive equity capital markets and private to public biotech operating experience. Key experiences include raising private and public capital, preparing private companies to enter the public markets, IPO execution from both the banking and biotech sides and advising on the allocation of capital.

Steven is currently the CFO of vTv Therapeutics. vTv is a clinical-stage, public company. It’s leading program, TPP399, is an adjunctive therapy to insulin for preventing hypoglycemia in Type 1 diabetics. Previously, Steven served as the Head of Corporate Development for Rallybio. He was primarily responsible for the Company’s financing and capital allocation strategy. Steven led Rallybio through all stages of its $92.7 million IPO in July 2021 and developed Rallybio’s long-term financing plan. Before joining Rallybio, he served as Managing Director, Head of U.S. Equity Capital Markets Originations for BMO Capital Markets, where he was responsible for building the firm’s equity capital markets business. Prior to assuming that role, Steven spent seven years as the Head of BMO’s Health Care Equity Capital Markets practice. While at BMO, Steven completed over 140 transactions raising over $20 billion. Previously, he was a Managing Director at Deutsche Bank Securities in New York, where his roles included Head of Health Care Equity Capital Markets, Head of Consumer and Business Services Equity Capital Markets and Head of Equity Private Placements. 

Steven received an MBA from Stanford University’s Graduate School of Business and a BBA from the University of Michigan. He currently serves on the Board of Trustees of Blythedale Children’s Hospital in Valhalla, NY.